nice quarterly report, page-11

I've just been re-reading the info on some of the products. PAT-SM6 is the next big one, targeting GRP78. I've also looked at a couple of scientific abstracts on GRP78 and cancer. It reads as if one of the big benefits of targeting GRP78 is because GRP78 not only promotes tumour expression, but makes tumours resistant to many treatments. So tackling it would be a very useful advance in cancer treatment.
http://cancerres.aacrjournals.org/content/67/8/3496

And as indicated on the PAB website, a good result for PAT-SM6 would be very positive for the rest of their natural human antibody products.
http://patrys.com.au/index.php/home/clinical-products/pat-sm6

If the coming report is good, PAB should go very well.

(I think I'm understating the potential but don't want to ramp up too much because biotechs at this stage of development are high risk. Also, steep sp rises without foundation aren't what I'm after as a long term investor in PAB. Steady continual sp rise is what I'm wanting :D)